LPTXAfter the bullish phase that ended at the end of 2023,
a bearish phase that could be concluded with a
long final wedge, so the bullish break of this figure
could be the signal of a bullish reversal,
otherwise towards new lows
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.93 USD
−81.41 M USD
0.00 USD
28.57 M
About Leap Therapeutics, Inc.
Sector
Industry
CEO
Doug E. Onsi
Website
Headquarters
Cambridge
Founded
2011
FIGI
BBG00DQ929W6
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Resistance become support LPTX already made breakout at the strongest resistance (3.02-3.16). Then, it also found to rebound back at the same level (resistance become support). From this point of view, the entry can be made at the range. The profit level found at 4.10 for 1st TP and 4.96 for 2nd TP. Drop you comment for furt
LPTX: Bullish Flag (60%)Bullish flag, not confirmed yet. Could confirm this coming week.
If confirmed:
Price target = 5.50$
Stay humble, have fun, make money!
$LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer,
$LPTXBroke out of ascending triangle
Currently back-testing the break-out
4hr hidden bullish divergence on the MACD and RSI
Stop = below diagonal support
Target = Resistance
LPTX Inv. H&S within WedgeI am looking at a break of the $2.60 level to confirm breakout.
-Price tightening within wedge for 3+ months (depending on how you draw the wedge) and completing what appears to be the right shoulder of an IH&S. (The midline, as I have drawn it, fits very neatly).
-Price has recently experienced bu
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly.
As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent.
The techn
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of LPTX is 2.91 USD — it has increased by 0.69% in the past 24 hours. Watch Leap Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Leap Therapeutics, Inc. stocks are traded under the ticker LPTX.
LPTX stock has fallen by −2.68% compared to the previous week, the month change is a 14.12% rise, over the last year Leap Therapeutics, Inc. has showed a −8.20% decrease.
We've gathered analysts' opinions on Leap Therapeutics, Inc. future price: according to them, LPTX price has a max estimate of 16.00 USD and a min estimate of 5.50 USD. Watch LPTX chart and read a more detailed Leap Therapeutics, Inc. stock forecast: see what analysts think of Leap Therapeutics, Inc. and suggest that you do with its stocks.
LPTX reached its all-time high on Apr 12, 2018 with the price of 102.50 USD, and its all-time low was 1.24 USD and was reached on Oct 2, 2023. View more price dynamics on LPTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LPTX stock is 3.89% volatile and has beta coefficient of 0.16. Track Leap Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Leap Therapeutics, Inc. there?
Today Leap Therapeutics, Inc. has the market capitalization of 111.50 M, it has decreased by −7.07% over the last week.
Yes, you can track Leap Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Leap Therapeutics, Inc. is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
LPTX earnings for the last quarter are −0.44 USD per share, whereas the estimation was −0.49 USD resulting in a 10.93% surprise. The estimated earnings for the next quarter are −0.40 USD per share. See more details about Leap Therapeutics, Inc. earnings.
Leap Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
LPTX net income for the last quarter is −18.18 M USD, while the quarter before that showed −20.13 M USD of net income which accounts for 9.70% change. Track more Leap Therapeutics, Inc. financial stats to get the full picture.
No, LPTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 54.00 employees. See our rating of the largest employees — is Leap Therapeutics, Inc. on this list?
Like other stocks, LPTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Leap Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Leap Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Leap Therapeutics, Inc. stock shows the sell signal. See more of Leap Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.